Evelo Biosciences, Inc. · OTC:EVLO
Evelo Biosciences — FY2019 Earnings Presentation
13 slides from Evelo Biosciences's earnings presentation, Feb 13, 2020
Slide 1: Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
Fourth Quarter and Full Year 2019 Financial Results and Business Highlights February 13, 2020
Slide 2: Legal disclaimer
Legal disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including
Slide 3: Evelo is targeting SINTAX, the small intestinal axis, to develop oral biologics
Evelo is targeting SINTAX™, the small intestinal axis, to develop oral biologics with potentially unparalleled safety and efficacy profiles Broad potential applicability for treating millions of people at all stages of disease 3
Slide 4: 2019 accomplishments: Validated platform, advanced potential blockbuster lead product
2019 accomplishments: Validated platform, advanced potential blockbuster lead product, continued pipeline progression • Validated Platform • Oral biologics targeting SINTAX can drive therapeutic effects throughout the body without systemic exposure • Clinical and preclinical data support broad platf
Slide 5: 2020 clinical priorities and expected milestones
2020 clinical priorities and expected milestones • Data from Phase 1b trial with new formulation 2Q 2020 EDP1815 • Initiate Phase 2 trial 2Q 2020 Psoriasis • Interim data from Phase 2 trial 4Q 2020 EDP1815 • Data from Phase 1b trial with new formulation 2Q 2020 Atopic Dermatitis EDP1867 • Initiate P
Slide 6: Evelo's platform has broad potential in chronic inflammation
Evelo’s platform has broad potential in chronic inflammation, a central driver of society’s most burdensome diseases Neurological diseases; 7M US DALYs, 111M WW “The contribution of inflammation in the pathogenesis of Alzheimer’s Disease has been appreciated only recently” Nat Rev Neuro, 2015 Chroni
Slide 7: 'Mild to moderate' psoriasis is a serious condition
‘Mild to moderate’ psoriasis is a serious condition • While characterized as mild to moderate in terms of body surface area, individual lesions can be severe • Significant number of individuals with mild to moderate disease are not treated at all due to physician concern about long-term safety or to
Slide 8: EDP1815 has achieved POC in mild to moderate psoriasis in two separate cohorts
EDP1815, has achieved POC in mild to moderate psoriasis in two separate cohorts Clinically meaningful reduction in PASI at high dose • EDP1815 was well tolerated with no overall difference in safety or tolerability reported from 10% placebo over 28 days of daily oral administration E R O C and at da
Slide 9: EDP1815 Phase 2 in mild to moderate psoriasis: dose ranging study
EDP1815 Phase 2 in mild to moderate psoriasis: dose ranging study with new improved formulation Trial Summary Summary of Endpoints • Randomized placebo-controlled dose ranging • Primary endpoint: Mean reduction in PASI score study ~180 individuals at 16 weeks • Evaluate three doses of new formulatio
Slide 10: Broad clinical and preclinical pipeline across therapeutic areas
Broad clinical and preclinical pipeline across therapeutic areas Product Preclinical Candidate Indication Development Phase 1 Phase 2 Phase 3 EDP1815 Psoriasis Phase 1b Phase 2 initiation expected 2Q 2020 EDP1815 Atopic Dermatitis Phase 1b Inflammation EDP1815 Inflammation1 EDP1867 Asthma EDP2939 In
Slide 11: Monoclonal microbials release faster from new formulation than enteric capsules
Monoclonal microbials release faster from new formulation than entericFasted A 9/21 capsules Gastric enablingFasted A 9/21 SIsuperior targeting of SINTAX Fasted B 9/21 Gastric Fasted B 9/21 SI Fasted C 9/21 Gastric Fasted C 9/21 SI Fasted E 9/25 Gastric Fasted D 9/25 SI Fasted Coated Tablet A Enteri
Slide 12: Financial Results and Concluding Remarks
Financial Results and Concluding Remarks 12
Slide 13: EVELO
EVELO